In patients with secondary mitral regurgitation (MR), at 2 years, transcatheter mitral valve replacement (TMVR) with mostly transapically implanted devices was associated with better clinical outcomes and symptomatic improvement and similar mortality in comparison with guideline-directed medical therapy (GDMT) alone, a new analysis shows.